对于IIb/III期黑色素瘤患者，辅助使用干扰素α-2b并不合理。 - Suppr

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

作者信息

Bajetta Emilio

机构信息

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy.

出版信息

Nat Clin Pract Oncol. 2008 Jan;5(1):4-5. doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

DOI:10.1038/ncponc1007

PMID:18043604

Abstract

摘要

相似文献

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

Nat Clin Pract Oncol. 2008 Jan;5(1):4-5. doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. doi: 10.1038/ncponc1004. Epub 2007 Nov 13.

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.

Adjuvant therapy of melanoma: what's new?

Melanoma Res. 2002 Jun;12(3):293-6. doi: 10.1097/00008390-200206000-00015.

Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.

Dermatology. 1995;191(3):234-9. doi: 10.1159/000246551.

Adjuvant interferon therapy for melanoma.

J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

[To outwit melanoma with its own tricks].

MMW Fortschr Med. 2003 Apr 10;145(15):4-6, 8, 10.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Lancet. 2005 Oct 1;366(9492):1189-96. doi: 10.1016/S0140-6736(05)67482-X.

Update on the role of adjuvant interferon for high risk melanoma.

Forum (Genova). 2000 Jul-Sep;10(3):230-9.

引用本文的文献

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.

Curr Oncol Rep. 2022 Oct;24(10):1273-1280. doi: 10.1007/s11912-022-01288-y. Epub 2022 May 31.

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.

Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.

PLoS One. 2019 Jan 28;14(1):e0211041. doi: 10.1371/journal.pone.0211041. eCollection 2019.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD008955. doi: 10.1002/14651858.CD008955.pub2.

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Expert Opin Pharmacother. 2011 Dec;12(17):2695-706. doi: 10.1517/14656566.2011.629187.

Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study.

Melanoma Res. 2011 Dec;21(6):547-54. doi: 10.1097/CMR.0b013e32834b58e4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献